Canada Pension Plan Investment Board Has $101.94 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Canada Pension Plan Investment Board grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 55.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 436,183 shares of the medical instruments supplier’s stock after purchasing an additional 155,990 shares during the period. Canada Pension Plan Investment Board owned approximately 0.15% of Becton, Dickinson and Company worth $101,940,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. WR Wealth Planners LLC boosted its holdings in Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC raised its holdings in shares of Becton, Dickinson and Company by 1.5% in the 1st quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock worth $731,000 after acquiring an additional 43 shares during the last quarter. Key Client Fiduciary Advisors LLC lifted its holdings in shares of Becton, Dickinson and Company by 2.6% in the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after purchasing an additional 43 shares in the last quarter. Clear Creek Financial Management LLC lifted its stake in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after acquiring an additional 44 shares in the last quarter. Finally, Edge Capital Group LLC lifted its position in shares of Becton, Dickinson and Company by 3.1% during the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock valued at $384,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.5 %

Becton, Dickinson and Company stock opened at $233.50 on Friday. The firm has a 50 day simple moving average of $235.51 and a 200 day simple moving average of $235.52. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $269.52. The firm has a market capitalization of $67.48 billion, a price-to-earnings ratio of 51.43, a P/E/G ratio of 1.91 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.96 earnings per share. On average, analysts predict that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be given a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on BDX shares. Raymond James decreased their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. The Goldman Sachs Group initiated coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 price objective on the stock. Evercore ISI lowered their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Finally, Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.